TORONTO, ONTARIO--(Marketwired - April 23, 2013) -Biologix Hair Inc. (OTCBB:BLGX) (OTCQB:BLGX) is pleased to report the Company's clinician licensing results for the period commencing February 1 through February 28, 2013.

During the month of February, Biologix Hair's worldwide Clinician Licensing Department, headquartered in Toronto, Canada, has contracted on behalf of Biologix with 75 new medical services clinics located in six countries - Great Britain (8), Ireland (2), Scotland (1), Spain (4), Wales (1) and the United States (59).

Based on information provided by the new contracting clinics, the total number of existing patients represented by these 75 clinics is 550,220, of which an estimated 264,395 would be interested in either the hair loss prevention or hair loss regeneration treatment and are candidates for the Biologix Hair Therapy System™.

The updated Clinician Licensing totals from inception through the end of February 2013 show:

• Number of countries in which clinicians have been contracted: Increased from 6 to 11
  
  
• Licensed medical clinics that have signed contractual reservations to become certified Biologix Hair Therapy Centers™: Increased from 121 to 196
  
  
• Total number of patients treated over the last 5 years by clinic network: Increased from 695,365 to 1,245,565
  
  
• Estimated number of existing patients who would be interested in either the hair loss prevention or hair loss regeneration treatment and are candidates for the Biologix Hair Therapy System™: Increased from 244,131 to 508,526
  

Donna Lieder, Biologix Vice President of Clinician Licensing, stated, "We are extremely pleased with the widespread receptivity we are experiencing from the global medical community as we continue developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists™ and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System™.

"We have been actively exhibiting at leading medical conferences around the world where top medical practitioners convene to discuss leading-edge developments within the medical community. Biologix Hair has proven to be one of the more actively discussed new medical discoveries amongst attendees and as a result, our global network of clinicians and its inherent universe of potential end-user patients continues to expand," continued Lieder.

Global Clinic Breakdown

The location on a country-by-country basis of all 196 clinics contracted as of February 28, 2013 is as follows:

• Bahamas (1)
• Canada (9 total, in 6 provinces): Alberta (3), British Columbia (1), Manitoba (1), New Brunswick (1), Nova Scotia (1) and Ontario (2)
• Cayman Islands (1)
• Great Britain (8)
• Ireland (2)
• Philippines (1)
• Scotland (1)
• Spain (4)
• Turks and Caicos (1)
• United States (108 total, in 37 states): Alabama (1), Arkansas (1), Arizona (2), Colorado (2), California (28), Connecticut (4), Delaware (1), Florida (11), Georgia (9), Indiana (5), Illinois (6), Kentucky (1), Maryland (2), Massachusetts (6), Michigan (5), Minnesota (4), Missouri (1), Nebraska (1), New Jersey (3), New Mexico (1), New York (10), Nevada (3), North Carolina (2), Ohio (9), Oklahoma (1), Oregon (2), Pennsylvania (5), Rhode Island (2), South Carolina (1), Tennessee (1), Texas (13), Utah (1), Virginia (2), Washington (8), West Virginia (1), Wisconsin (2) and Wyoming (2).
• Wales (1)

Here is what a couple of contracted clinicians had to say about why they decided to contract to join the certified Biologix Hair Therapy Center™ team:

Dr. Allan Patrick, Director of Atlantic Hair Restoration said, "We see a lot of consultations for hair loss issues, and not all patients are candidates for hair transplantation. Many have milder cases that are not well treated with traditional medical or topical laser therapy. I have been waiting for an effective minimally invasive therapy for mild-moderate hair loss. At the ISHRS annual meeting in Nassau, I was excited to learn of the potential to treat this segment of my patient population with the new product coming from Biologix. I am anxious to be one of the first to use this exciting new product, and to be a regional distributor."

Dr. Richard S. Wilkinson of the Wilkinson Wellness Clinic said, "As a physician who has been practicing integrative and anti-aging medicine for many years, I find the Biologix Hair opportunity a wonderful offer.

"In Anti-Aging Medicine, or, as some would describe the field, Age Management Medicine, our primary goal is to help our patients achieve and maintain high-level wellness. Another aspect of aging that deserves attention is the aesthetics of an older person. Typically we feel better if we think we look good. And for some aging folk, the hair status is a very big deal. We feel that we look more sickly when we have lost substantial amounts of our hair. When we feel better, we want to look better.

"Biologix Hair offers an opportunity to help our aging population, whether 25 years old or 75 years, experience a higher level of overall wellness both inside and outside. I believe our patients will appreciate the opportunity to complement their internal improvements with external, visual improvements.

"Another important and practical reason for my interest is the political status of medical practice. We, certainly I, have little idea of the future impact of the so-called Obamacare scheme on the viability of my private practice. It seems to me that Biologix Hair could provide a method of financial viability during a time of economic turmoil upcoming in the field of medicine."

About Biologix Hair Inc. and Biologix Hair Science Ltd.

Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. ™ (BHS), is focused on realizing the full market potential for its patent-pending hair loss formula - Biologix Revive - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.

Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.

BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT). The R&D program, expected to take approximately twelve months to complete, is an important final step before formal clinical trials and the FDA approval process begins.

Additionally, on May 11, 2012, Venable LLC, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO), to which 144 countries have as of now contracted, including Canada and the United States.

Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy System™, if and when FDA and other major market approvals are forthcoming.

As BHS advances the regulatory approval process, Biologix Hair, together with wholly owned subsidiary companies operated by BHS, are rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists™ and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System™.

Biologix Hair has decided not to risk creating any potential regulatory conflicts by offering treatment outside the United States and other major high-product-margin markets until FDA approval has been granted. Therefore, the Biologix Hair Therapy System™ is not yet available other than to the 5,000+ patients who participated in the pre-clinical-trials conducted in South America.

To learn more about Clinician Licensing opportunities, [ Click Here ].

Disclaimer

This announcement is not an offer to sell any Biologix Hair Inc. ("Biologix") securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of Biologix may contain "forward-looking statements". Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and includes, without limitation, the development of treatment centers and approval from regulatory authorities. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise. In Canada, Europe and the United States, the Biologix treatment is not approved for use by Health Canada, EMA or the FDA. The company makes no representations that it will receive Health Canada, EMA or FDA approvals.

Contributing Sources

---

Market Wire